Market Overview

UPDATE: Loewen Ondaatje McCutcheon Downgrades BioMimetic Therapeutics to Hold, Reiterates $7.50 PT

Related BMTI
UPDATE: Wedbush Terminates Coverage on BioMimetic Therapeutics on Acquisition by Wright Medical
Loewen Ondaatje McCutcheon Reiterates Buy Rating, $7.50 PT on BioMimetic Therapeutics

In a report published Wednesday, Loewen Ondaatje McCutcheon downgraded its rating on BioMimetic Therapeutics (NASDAQ: BMTI) from Buy to Hold, but reiterated its $7.50 price target.

Loewen Ondaatje McCutcheon noted, “With BMTI trading within proximity of our 12-month price target of $7.50 per share, we have downgraded the shares to Hold (from Buy), reflecting a more balanced risk/reward profile.”

BioMimetic Therapeutics closed on Tuesday at $6.94.

Latest Ratings for BMTI

DateFirmActionFromTo
Mar 2013Wells FargoSuspendsNeutral
Nov 2012Loewen, Ondaatje, McCutcheon DowngradesBuyHold
Oct 2012Loewen, Ondaatje, McCutcheonInitiates Coverage onBuy

View More Analyst Ratings for BMTI
View the Latest Analyst Ratings

Posted-In: Loewen Ondaatje McCutcheonAnalyst Color Downgrades Analyst Ratings

 

Related Articles (BMTI)

Around the Web, We're Loving...

Get Benzinga's Newsletters